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Objective Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR)
gene, continues to present diagnostic challenges. Newborn screening and an evolving understanding of CF ge-
netics have prompted a reconsideration of the diagnosis criteria.
Study design To improve diagnosis and achieve standardized definitions worldwide, the CF Foundation con-
vened a committee of 32 experts in CF diagnosis from 9 countries to develop clear and actionable consensus guide-
lines on the diagnosis of CF and to clarify diagnostic criteria and terminology for other disorders associated with
CFTR mutations. An a priori threshold of ≥80% affirmative votes was required for acceptance of each recommen-
dation statement.
Results After reviewing relevant literature, the committee convened to review evidence and cases. Following the
conference, consensus statements were developed by an executive subcommittee. The entire consensus com-
mittee voted and approved 27 of 28 statements, 7 of which needed revisions and a second round of voting.
Conclusions It is recommended that diagnoses associated with CFTR mutations in all individuals, from newborn
to adult, be established by evaluation of CFTR function with a sweat chloride test. The latest mutation classifica-
tions annotated in the Clinical and Functional Translation of CFTR project (http://www.cftr2.org/index.php) should
be used to aid in diagnosis. Newborns with a high immunoreactive trypsinogen level and inconclusive CFTR func-
tional and genetic testing may be designated CFTR-related metabolic syndrome or CF screen positive, inconclu-
sive diagnosis; these terms are now merged and equivalent, and CFTR-related metabolic syndrome/CF screen
positive, inconclusive diagnosis may be used. International Statistical Classification of Diseases and Related
Health Problems, 10th Revision codes for use in diagnoses associated with CFTR mutations are included. (J Pediatr
2017;181S:S4-15).
Cystic fibrosis (CF) is the most common life-threatening autosomal reces-sive disease in the US, affecting approximately 1 in 4000 newborns in theUS,1-3 and occurring at higher frequencies in some European countries.4,5
CF is a multisystem disorder caused by mutations in the gene for the CF trans-
membrane conductance regulator (CFTR), which encodes an ion channel protein,6
with more than 2000 mutations identified to date (http://www.genet.sickkids.on.ca/
cftr/app7).
A diagnosis of CF initially relied on phenotype, with clinical recognition of char-
acteristic signs and symptoms.8,9 However, because of widespread CF newborn
screening (NBS), at least 64% of new CF diagnoses in the US now occur in
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CFSPID CF screen positive, inconclusive diagnosis
CFTR CF transmembrane conductance regulator
CFTR2 Clinical and Functional Translation of CFTR
CRMS CFTR-related metabolic syndrome
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asymptomatic or minimally symptomatic infants following a
positive NBS result.10 Although the majority of infants who
screen positive can be readily diagnosed with CF after a con-
firmatory test showing high sweat chloride concentration, the
diagnosis is not clear in some individuals,11,12 leading to per-
sistent challenges13 and stresses, including a potentially dis-
turbed parent/child relationship.14-16 Furthermore, universal NBS
was implemented only recently in the US, and many individu-
als born prior to 2010 have not been screened. Diagnosis of
CF in the nonscreened population can be challenging because
the age of onset and severity of symptoms can differ greatly
as a result of highly variable levels of CFTR dysfunction. Pre-
senting manifestations can include pancreatitis, respiratory
symptoms, chronic sinusitis, and male infertility.9,17-19
The last few years have seen significant growth of pheno-
typic and genotypic information on CF that can help with in-
terpretation of the disease status in many patients. International
collection of clinical data from individuals with CF20 and labo-
ratory advances21 provide insight into the functional and physi-
ological impact of the most common mutations.22 Because of
this new information, and to seek harmony with the diagnos-
tic criteria and terminology23 of the European CF Society
(ECFS), it was decided that the 2008 diagnostic guidelines24
of the CF Foundation should be revised.
The CF Foundation convened an international committee
of experts in the diagnosis of CF to update diagnostic guid-
ance and achieve standardization in definitions worldwide. The
mission of this committee was to develop clear and action-
able consensus guidelines on diagnosis of CF and other con-
ditions associated with mutations in the CFTR gene such as
CFTR-relatedmetabolic syndrome (CRMS)25 or CF screen posi-
tive, inconclusive diagnosis (CFSPID),26 and CFTR-related
disorders.27 The recommendations in this article address in-
dividuals with both clear and unclear diagnoses, including
infants with positive NBS (defined as any result other than
normal) and/or prenatal diagnosis,28 and individuals with CF-
like symptoms who were either never screened or who had false
negative newborn or prenatal screening results.9 Case studies,
designed to show how the recommendations should be applied
in challenging clinical scenarios, can be found in additional
articles published throughout this Supplement.9,28,29
Methods
An international consensus committee was selected and tasked
with the development of guidelines on the diagnosis of CF;
32 experts made up this committee. Committee selection was
designed to include participants representative of worldwide
CF care communities, particularly pediatric CF providers with
NBS experience, and other relevant specialists, including adult
CF providers. Before the consensus conference, the commit-
tee reviewed the existing CF Foundation diagnosis guidelines24
and a list of publications on CF diagnosis published since the
2008 CF Foundation Diagnosis Guidelines, including 10 key
articles selected by conference cochairs. The conference was
held immediately prior to the North American CF Confer-
ence in October 2015.
At the consensus conference, committee members pre-
sented and discussed new studies and data on CF diagnosis.
An executive subcommittee, consisting of 10 representatives
from 4 countries, developed the consensus statements at sub-
sequent meetings. These statements were reviewed by the entire
consensus committee and voted on by the members using an
electronic survey tool (SurveyMonkey, Palo Alto, California).30
An a priori threshold of ≥80% affirmative votes was re-
quired for acceptance. Individuals voting against a statement
were asked to provide a revised statement and/or explana-
tion for their vote. Feedback on the statements that did not
reach 80% agreement was reviewed by the committee co-
chairs, and those statements were revised with input from the
rest of the executive subcommittee. The revised statements were
then resubmitted for voting.
After the recommendation statements were agreed upon, they
were presented to the ECFS at the Diagnostic NetworkWorking
Group annual meeting in February 2016 to help engage all
parties in the discussion. The draft manuscript was distrib-
uted for feedback from the executive subcommittee, confer-
ence committee, the CF Foundation’s CF Center Committee,
all CF centers in the US, parents of screened infants, and a
variety of international organizations and their members during
a public comment period.
Results
In the survey, participants were able to vote in agreement, dis-
agreement, or to abstain. However, in each of the 2 surveys dis-
tributed for reviewing the consensus statements and voting,
1 committee member (a different person each time) did not
respond. Thus, the 1 committee member who did not par-
ticipate in the first voting exercise did not constitute an ab-
stention. A vote was taken on 28 statements initially; 8 did not
reach at least 80% agreement. The 8 statements that did not
pass were reviewed and revised, and reduced to 7 statements
by the chairs and the executive committee and sent out for a
second round of voting. All but 1 member of the 32 commit-
tee members participated in this vote (ie, 1 was nonrespon-
sive). All 7 of the revised statements passed the 80% threshold
in the second round of voting.
The committee approved 27 consensus statements (Table I)
in 4 overlapping categories that apply to: (1) both screened and
nonscreened populations; (2) newborn screened popula-
tions and fetuses undergoing prenatal testing; (3) infants with
uncertain diagnosis and designated either CRMS or CFSPID
(now considered to be the same); and (4) patients presenting
clinically who represent nonscreened populations, including
children born at home or in regions before NBS implemen-
tation, those with false negative screening tests, and older
nonscreened individuals.
The Figure provides a simplified algorithm for how these
consensus statements should be applied to individuals sus-
pected of having CF because of a positive NBS result, the ap-
pearance of signs or symptoms, or recognition of immediate
family history of CF (most often sibling, but may also include
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Table I. Consensus recommendations for diagnosis of CF*
Statement
numbers Consensus statements Vote
Abstain
(n)
1 Sweat chloride testing should be performed according to approved procedural guidelines published in established, international
protocols such as the CLSI 2009 Guidelines.
100% 0
2 Newborns with a positive CF newborn screen, to increase the likelihood of collecting an adequate sweat specimen, should have
the test performed bilaterally and when the infant weighs >2 kg, and is at least 36 wk of corrected gestational age.
87% 0
3 Newborns greater than 36 wk gestation and >2 kg body weight with a positive CF newborn screen, or positive prenatal genetic
test, should have sweat chloride testing performed as soon as possible after 10 d of age, ideally by the end of the neonatal
period (4 wk of age).
93% 1
4 In infants with presumptive CF identified through NBS, CF treatment should not be delayed while efforts to establish a diagnosis
of CF are initiated.
83% 1
5 Sweat chloride analysis should be performed within a few hours of sweat collection and the results and interpretations should
be reported to clinicians and parents or patients, as soon as possible and certainly on the same day.
90% 0
6 In individuals presenting with a positive newborn screen, clinical features consistent with CF, or a positive family history, a
diagnosis of CF can be made if the sweat chloride value is ≥60 mmol/L.
93% 0
7 Individuals who are screen-positive and meet sweat chloride criteria for CF diagnosis should undergo CFTR genetic testing if
the CFTR genotype was not available through the screening process or is incomplete.
100% 0
8 In individuals with a positive newborn screen, a sweat chloride <30 mmol/L indicates that CF is unlikely. 82% 2
9 Individuals with clinical features that may be consistent with CF who have a sweat chloride <30 mmol/L indicates that CF is
less likely. It may, however, be considered if evolving clinical criteria and/or CFTR genotyping support CF and not an
alternative diagnosis.
80% 0
10 Individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, and sweat chloride values in
the intermediate range (30-59 mmol/L) on two separate occasions may have CF. They should be considered for extended
CFTR gene analysis and/or CFTR functional analysis.
90% 0
11 The latest classifications identified in the CFTR2 project (http://www.cftr2.org/index.php) should be used to aid with CF
diagnosis:
• CF-causing mutation: individuals with 2 copies on separate alleles will likely have CF (clinical sweat confirmation needed)
• Mutation of varying clinical consequence (MVCC): a mutation that in combination with a CF-causing mutation or another
MVCC mutation may result in CF
• Uncharacterized mutation/mutation of UNK: mutation that has not been evaluated by CFTR2 and may be disease causing or
of variable clinical consequence or benign
• Non-CF-causing mutation: individuals with 1 or more are unlikely to have CF (as a result of that allele)
100% 0
12 In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2
CF-causing mutations (defined by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to
confirm the diagnosis.
87% 0
13 The absence of detection of 2 CF-causing CFTR mutations does not exclude a diagnosis of CF. 93% 1
14 If further CF functional testing is needed (NPD and ICM), it should be performed in a validated reference center with trained staff
certified by the CF Foundation TDN or ECFS Clinical Trial Network.
100% 0
15 In individuals with a positive newborn screen but variable or uncharacterized CFTR mutations (<2 CF-causing mutations), the
diagnosis of CF can be made by demonstrating CFTR dysfunction (a sweat chloride ≥ 60 mmol/L or CF-typical NPD or ICM).
93% 0
16 The term CRMS is used in the US for healthcare delivery purposes and CFSPID is used in other countries, but these both
describe an inconclusive diagnosis following NBS.
96% 2
17 The term CRMS/CFSPID is reserved for individuals who screen positive without clinical features consistent with a diagnosis of
CF.
83% 1
18 The definition of CRMS/CFSPID is an infant with a positive NBS test for CF and either:
• A sweat chloride value <30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences
OR
• An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations
86% 1
19 Children designated as CRMS/CFSPID should undergo at least one repeat sweat chloride test at CF centers with suitable
expertise, such as an accredited CF center.
86% 1
20 Children designated as CRMS/CFSPID should have clinical evaluation performed by CF providers to identify the minority that
may develop clinical symptoms.
83% 1
21 Children designated as CRMS/CFSPID can be considered for extended CFTR gene analysis (sequencing and or deletion
duplication testing), as well as CFTR functional analysis (NPD/ICM) testing to further define their likelihood of developing CF.
80% 0
22 The decision to reclassify children designated as CRMS/CFSPID as CF is an integrated decision that should take into account
functional assessment of CFTR (sweat chloride, and possibly NPD/ICM), CFTR genetic analysis, and clinical assessment by
the CF clinicians caring for the patient.
90% 0
23 Genetic counseling should be offered to families of individuals followed for CRMS/CFSPID, including a discussion of the risk in
future pregnancies.
100% 1
24 Research Recommendation: Infants with a designation of CRMS/CFSPID (by definition) do not have clinical features consistent
with a diagnosis of CF and further research is needed to determine the prognosis and best practices for frequency and
duration of follow-up.
96% 0
25 For individuals presenting with CF symptoms, the same diagnostic criteria recommended for the screened population for sweat
chloride testing, CFTR genetic analysis, and CFTR functional testing should be used to confirm a CF diagnosis.
93% 0
26 The diagnosis of CFTR-related disorder has been defined as a monosymptomatic clinical entity (CBAVD/pancreatitis/
bronchiectasis) associated with CFTR dysfunction that does not fulfill the diagnostic criteria for CF.
86% 2
27 Clinicians should avoid the use of terms like classic/nonclassic CF, typical/atypical CF, delayed CF, because these terms have no
harmonized definition and could be confusing for families or caregivers.
83% 1
CBAVD, congenital bilateral absence of the vas deferens; CLSI, Clinical and Laboratory Standards Institute; CTN, Clinical Trial Network; ICM, intestinal current measurement; MVCC, mutation of
varying clinical consequence; NPD, nasal potential difference; TDN, Therapeutics Development Network; UNK, unknown clinical consequence.
*In each of the 2 surveys distributed for reviewing the consensus statements drafted and voting, 1 committee member, a different person each time, did not respond.
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parent or child). It should be noted that a positive NBS result
does not mean the infant has CF; the probability of a CF di-
agnosis following a positive result varies greatly depending on
the NBS method used.
Even though many individuals enter this algorithm through
a positive newborn screen in which CFTR genetic testing was
done, the diagnosis of CF is primarily based on the direct dem-
onstration of abnormal CFTR function by measurement of
chloride concentration in the sweat.24 Although obtaining an
adequate sweat specimen for chloride measurements can be
challenging, particularly in very young infants, experience and
studies have shown that this is feasible in full-term infants
during the first postnatal month (ie, during the neonatal
period).31-34 Following the committee’s recommendations will
improve reliability of the sweat test result.
Sweat Chloride Testing and Presumptive Diagnosis
(1) All populations: Sweat chloride testing should be per-
formed according to approved procedural guidelines
published in established, international protocols such as the
Clinical and Laboratory Standards Institute 2009 Guide-
lines. Following appropriate protocols for performing the
sweat test32 is important for achieving accurate results and
minimizing collection of inadequate amounts of sweat
(quantity not sufficient).28,33-37
(2) For newborns: Newborns with a positive CF newborn screen,
to increase the likelihood of collecting an adequate sweat speci-
men, should have the test performed bilaterally and when
the infant weighs >2 kg and is at least 36 weeks’ corrected
gestational age. Sweat samples collected bilaterally must not
be combined; instead, they should be analyzed sepa-
rately, providing a useful quality control measure.33
(3) For newborns: Newborns greater than 36 weeks’ gestation
and >2 kg body weight with a positive CF newborn screen,
or positive prenatal genetic test, should have sweat chloride
testing performed as soon as possible after 10 days of age,
ideally by the end of the neonatal period (4 weeks of age).
For a variety of reasons related to efficient, effective follow-
up and optimizing care, sweat chloride testing should occur
as soon as possible when positive screening results are
reported and can be as early as 48 hours after birth.33
The committee recognizes that many NBS programs do
not report results by this time and, therefore, recom-
mends that sweat chloride testing proceed as soon as pos-
sible after results are available; generally, this is no later
than 10 days of age. Although gestational age and weight
must be considered,38 testing should occur if at all pos-
sible before the end of the neonatal period because mal-
nutrition and other risks such as potentially fatal
hyponatremic dehydration may occur even in the first
few weeks of life.39-42
Figure. CF is diagnosed when an individual has both a clinical presentation of the disease and evidence of CFTR dysfunc-
tion. The tests of CFTR function are not always done in this order, but hierarchically to establish the diagnosis of CF, sweat
chloride should be considered first, then CFTR genetic analysis, and then CFTR physiologic tests. All individuals diagnosed
with CF should have a sweat test and a CFTR genetic analysis performed. Rare individuals with a sweat chloride <30 mmol/L
may be considered to have CF if alternatives are excluded and the other confirmatory tests (genetic, physiologic testing) support
CF. If only 1 CFTR variant is identified on limited analysis, further (“extended”) CFTR testing should be performed.22 CF is
possible if both alleles possess CF-causing, undefined, or mutation of varying clinical consequence (MVCC) mutations; CF is
unlikely if only non-CF-causing mutations are found. If a CF diagnosis is not resolved, CRMS/CFSPID (following NBS) or CFTR-
related disorder should be considered.9,29 Rarely, no distinct label may be appropriate but further follow-up may be warranted.
In these cases, the use of “CF carrier” or the specific clinical problem should be used for characterization/labeling purposes.
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(4) For newborns: In infants with presumptive CF identified
through NBS, CF treatment should not be delayed while
efforts to establish a diagnosis of CF are initiated. Optimal
outcomes depend on early intervention. Efforts to obtain
adequate quantities of sweat and accurate sweat chloride
values should not delay start of salt supplementation or
other appropriate therapies.43 The CF Foundation rec-
ommends that infants with CF have an initial visit at an
accredited CF care center within 24-72 hours of diagnosis,43
and timing of the initial visit for infants with a presump-
tive diagnosis should aim to meet this timeframe. A pre-
sumptive diagnosis of CF for purposes of treatment
initiation can include the following clinical circum-
stances: (1) positive CF newborn screen showing 2 CF-
causing CFTR mutations (see below); (2) positive CF
newborn screen and clinical signs and symptoms of CF;
and (3) meconium ileus, with or without a positive
newborn screen.
However, definitive diagnosis requires demonstration of
CFTR dysfunction.A date of presumptive diagnosis should
be recorded to permit evaluation of timeliness of diag-
nosis and treatment within NBS programs. However, for
purposes of providing standardized data to the CF Foun-
dation Patient Registry, the date of the first positive sweat
chloride test should be reported as the date of diagnosis.
(5) All populations: Sweat chloride analysis should be per-
formed within a few hours of sweat collection, and the results
and interpretations should be reported to clinicians and
parents or patients, as soon as possible and certainly on the
same day. Prompt reporting should be made regardless of
sweat test results to reduce family or patient stress.44-47 A
second, confirmatory, sweat test following an initial posi-
tive result is not necessary; this is a change from previ-
ous CF Foundation diagnostic guidelines.24,48
Sweat Chloride Test Results ≥60 mmol/L
(6) All populations: In individuals presenting with a positive
newborn screen, clinical features consistent with CF, or a posi-
tive family history, a diagnosis of CF can be made if the sweat
chloride value is ≥60 mmol/L. Even though the sweat test
is commonly used for diagnosis of individuals present-
ing with symptoms of CF, many newborns are reported
as having CF based solely on a positive NBS result.
However, NBS tests must always be considered as screen-
ing procedures and not diagnostic studies. The genetic
analysis included as part of many NBS programs must not
be relied upon for conclusive diagnosing and/or
genotyping, as errors can arise from problems with Guthrie
card labelling,49,50 changes in the mutation panel used by
the NBS program (eg, as described byWatson et al51), NBS
laboratory errors including DNAmisinterpretations, or de-
tection of 2 CFTR mutations in cis (ie, on the same
chromosome).22,52,53 All of these problems have occurred
and will occur again.
(7) For newborns: Individuals who screen positive and meet
sweat chloride criteria for CF diagnosis should undergo CFTR
genetic testing if the CFTR genotype was not available through
the screening process or is incomplete. Genetic testing is an
important part of the diagnostic work-up, and it is not
uncommon for a positive NBS result to include the rec-
ognition of 2 CF-causing mutations. Even in the pres-
ence of a positive sweat test, the identification of 2 CF-
causing mutations should be confirmed in a clinical
genetics laboratory capable of performing in-depth genetic
analysis when required to further define CF risk (eg, the
length of polyT tracts with the c.350G>A [legacy: R117H]
CFTR mutation).54,55 Confirmation of genetic testing results
with an FDA-approved companion diagnostic test also has
additional value in therapy selection56 and access.57,58
Sweat Chloride Test Results <30 mmol/L
(8) For newborns: In individuals with a positive newborn screen,
a sweat chloride <30 mmol/L indicates that CF is unlikely.
Sweat chloride testing may be repeated if indicated by
family history, or if symptoms suggestive of CF occur.
(9) All populations: Individuals with clinical features that may
be consistent with CF who have a sweat chloride <30 mmol/L
indicates that CF is less likely. It may, however, be consid-
ered if evolving clinical criteria and/or CFTR genotyping
support CF and not an alternative diagnosis. The level of
sweat chloride below which CF is considered unlikely is
30 mmol/L for all age groups. This is a change from pre-
vious guidelines for individuals >6 months of age (the pre-
vious limit was 40 mmol/L) because patients have been
definitively diagnosed with CF with chloride values in the
30-39 mmol/L range.
Details regarding the diagnosis of CF in the very rare
individual with sweat chloride <30 mmol/L are pub-
lished elsewhere.22 Some CFTR mutations, such as
c.3717 + 12191C>T (legacy: 3849 + 10 kb C- > T), are as-
sociated with low sweat chloride values; in these cases, an
alternative diagnosis does not need to be ruled out.9,59,60
Sweat Chloride Test Results of 30-59 mmol/L
(10) All populations: Individuals presenting with a positive
newborn screen, symptoms of CF, or a positive family history,
and sweat chloride values in the intermediate range (30-
59 mmol/L) on 2 separate occasions may have CF. They
should be considered for extended CFTR gene analysis and/
or CFTR functional analysis. Individuals with sweat chlo-
ride concentrations in the intermediate range will need
further study to establish or rule out a CF diagnosis.12,61-63
Evidence may be provided by CFTR genotype20 (an article
in this Supplement provides a discussion of CFTR genetic
testing and interpretation in detail22) or by further CFTR
physiologic testing.64-67 Other articles in this Supple-
ment present a discussion of the demonstration of CFTR
dysfunction including the use of nasal potential differ-
ence (NPD) or intestinal current measurement (ICM) on
the screen-positive newborn28 and information on the
symptomatic patient.9
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Next Steps for Intermediate Sweat Test Results
(11) All populations: The latest classifications identified in the
Clinical and Functional Translation of CFTR (CFTR2)
project20 should be used to aid with CF diagnosis: (1) CF-
causing mutation: individuals with 2 copies on separate
alleles will likely have CF (clinical sweat confirmation
needed). (A sweat chloride test result ≥30 mmol/L is con-
firmatory for patients with this genotype); (2) muta-
tion of varying clinical consequence: A mutation that in
combination with a CF-causing mutation or another mu-
tation of varying clinical consequence mutation may result
in CF; (3) uncharacterized mutation/mutation of unknown
clinical consequence: mutation that has not been evalu-
ated by CFTR2 and may be disease causing or of variable
clinical consequence or benign; and (4) non-CF-causing mu-
tation: individuals with 1 or more are unlikely to have CF
(as a result of that allele).
The CFTR2 project provides a detailed characteriza-
tion of CFTR mutations by collecting clinical and
laboratory evidence of phenotypic consequence.20 For
each mutation, the CFTR2 website provides informa-
tion and classification as listed above. The CFTR2 project
is updated as mutation-specific functional analyses are
completed. Also, because mutation categorization may
change over time, it is important to confirm genotype
interpretation on the most current version of the website.
Mutations that are not analyzed as part of CFTR2 may
still be interpretable if adequate research exists. For
example, if a mutation is detected that is not annotated
in CFTR2 and has been shown to be seen previously in
patients with CF, has functional evidence that the
nucleotide/protein change is deleterious; and does not
occur commonly in databases of general (healthy)
population, that mutation can be characterized as
CF-causing.22
(12) All populations: In individuals presenting with a positive
newborn screen, symptoms of CF, or a positive family history,
the identification of 2 CF-causing mutations (defined by
CFTR2) is consistent with a diagnosis of CF. Sweat chlo-
ride testing is necessary, though, to confirm the diagnosis.
A sweat chloride test result ≥30 mmol/L is confirma-
tory in individuals with 2 CF-causing mutations on sepa-
rate chromosomes. As stated above, there are situations
in which repeated sweat chloride testing does not provide
further clarity, such as in individuals with CFTR muta-
tions known to be associated with normal or interme-
diate sweat chloride.59,60 Another article in this Supplement
provides further exploration of this topic.9
(13) All populations: The absence of detection of 2 CF-causing
CFTR mutations does not exclude a diagnosis of CF.
Because classification and identification of CF-causing
CFTR mutations is ongoing, there are individuals with
a CF diagnosis in whom 2 CFTR mutations have not been
detected. Thus, even though the CFTR2 initiative has been
a valuable step forward in improving the diagnostic char-
acterization of patients with CFTR mutations, it does not
take the place of clinical observation and expertise. Other
articles in this Supplement present more in-depth dis-
cussions on this topic. 9,22,29
To explore further a CF diagnosis in individuals with a
positive newborn screen, symptoms of CF, or a positive
family history, intermediate sweat chloride values (30-
59 mmol/L), and fewer than 2 CF-causing mutations, the
committee recommends additional CFTR physiologi-
cal testing that directly measures CFTR function, such
as NPD and ICM.68
(14) All populations: If further CF functional testing is needed
(NPD and ICM), it should be performed in a validated ref-
erence center with trained staff certified by the CF Foun-
dation Therapeutics Development Network or ECFS Clinical
Trial Network. When performed correctly, NPD can dis-
criminate a wide range of CFTR function.69,70 ICM also
can be used to confirm a diagnosis of CF in the context
of intermediate sweat chloride levels,66-68,70-73 and may be
useful when NPD testing is unsuccessful (eg, when at-
tempting to conduct NPD testing in the uncooperative
child) (I Sermet-Gaudelus, personal communication,
October 2015). Few CF centers in the US are prepared
to conduct these tests. However, the added value that the
results have provided to situations of diagnostic uncer-
tainty (especially in Europe where they are more widely
used) suggests that there will be widespread uptake of
the tests in the future. There are patients with interme-
diate sweat chloride test results and an undefined CFTR
genotype for whom NPD or ICM testing could provide
diagnostic clarity; these patients should be seen in centers
certified for the test in their country. Another article in
this Supplement presents further discussion of NPD and
ICM testing.28
(15) For newborns: In individuals with a positive newborn screen
but variable or uncharacterized CFTR mutations (<2 CF-
causing mutations), the diagnosis of CF can be made by
demonstrating CFTR dysfunction (a sweat chlo-
ride ≥60 mmol/L or CF-typical NPD or ICM). Identifi-
cation of diagnostic levels for NPD and ICM
measurements must be performed at the level of the ref-
erence center conducting the tests. Another article in this
Supplement presents further discussion on this topic.28
For the Newborn with an Inconclusive Diagnosis
(16) For newborns: The term CRMS is used in the US for
healthcare delivery purposes and CFSPID is used in other
countries, but these both describe an inconclusive diagno-
sis following NBS. Newborn infants with a high level of
immunoreactive trypsinogen (IRT) and inconclusive
CFTR functional and genetic testing may be labeled either
CRMS or CFSPID.25,26,29 CFSPID describes the incon-
clusive nature of the condition in a manner that is
easy for patients and families to understand and can be
designated by International Statistical Classification of Dis-
eases and Related Health Problems, 10th Revision (ICD-
10) code P09. However, because of the US healthcare
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system requirements,74 CRMS (ICD-10 code E88.89) must
be used in clinical settings in the US for continuing,
follow-up care. These 2 terms are nearly identical, and
the consensus committee recommends that the 2 terms
be harmonized, for improved international communi-
cations and analysis of clinical outcomes. The term
CRMS/CFSPID will be used throughout this Supple-
ment and is recommended.75
(17) For newborns: The term CRMS/CFSPID is reserved for in-
dividuals who screen positive without clinical features con-
sistent with a diagnosis of CF. The CRMS/CFSPID
diagnosis should not be used in other clinical sce-
narios, including those involving individuals who have
not received a positive NBS result, or individuals who have
clinical symptoms attributable to CFTR dysfunction.9
(18) For newborns: The definition of CRMS/CFSPID is an
infant with a positive NBS test for CF and either: (1) sweat
chloride value <30 mmol/L and 2 CFTR mutations, at least
1 of which has unclear phenotypic consequences; or (2) in-
termediate sweat chloride value (30-59 mmol/L) and 1 or
0 CF-causing mutations. Individuals designated as CRMS/
CFSPID initially appear asymptomatic and may never
develop CF symptoms; however, they should be re-
ferred to a CF specialist at an accredited CF care center
to ensure there are no hidden signs or symptoms of CF
and to establish a plan for follow-up.25,76
Next Steps in the Newborn with CRMS/CFSPID
Designation
(19) For newborns: Children designated as CRMS/CFSPID
should undergo at least 1 repeat sweat chloride test at CF
centers with suitable expertise, such as an accredited CF
center. This test should be used to confirm the CRMS/
CFSPID designation. Appropriate timing for the repeat
sweat chloride test is discussed elsewhere in this
Supplement.29
(20) For newborns: Children designated as CRMS/CFSPID
should have clinical evaluation performed by CF provid-
ers to identify the minority that may develop clinical symp-
toms. This group of children must be monitored for
development of symptoms, and surveillance evalua-
tions conducted (respiratory tract cultures, imaging,
and spirometry or lung-clearance index when age-
appropriate). Measuring fecal elastase levels or follow-
ing IRT or pancreatitis associated protein trends may be
considered if clinically indicated to identify CF clinical
manifestations (phenotypes) objectively.11,25,76-78 CF cannot
be diagnosed through the identification of elevated levels
of IRT alone; elevated IRT can occur in the context of
other tissue stress.79,80 Another article in this Supple-
ment presents information about appropriate timing for
monitoring.29
(21) For newborns: Children designated as CRMS/CFSPID can
be considered for extended CFTR gene analysis (sequenc-
ing and or deletion duplication testing), as well as CFTR
functional analysis (NPD/ICM) testing to further define
their likelihood of developing CF. Other articles in this
Supplement present information on the genetic tests that
are useful in this scenario and useful functional analy-
sis testing.22,29
(22) For newborns: The decision to reclassify children desig-
nated as CRMS/CFSPID as CF is an integrated decision
that should take into account functional assessment of CFTR
(sweat chloride, and possibly NPD/ICM), CFTR genetic
analysis, and clinical assessment by the CF clinicians caring
for the patient. The decision to change a designation from
CRMS/CFSPID to CF is a difficult one and should be
made by an experienced CF physician.25,26,29
(23) For newborns: Genetic counseling should be offered to fami-
lies of individuals followed for CRMS/CFSPID, including
a discussion of the risk in future pregnancies. The CF Foun-
dation recommends that genetic counseling be offered
to all families of newborns diagnosed with CF.24 This is
also important for families of newborns designated
CRMS/CFSPID. Our understanding of the impact of
various CFTR mutations is evolving and will continue
to be clarified for many years. Genetic counseling is im-
portant for parents to understand the risk of a child
having CF or being designated as CRMS/CFSPID in future
pregnancies.25,26
(24) For newborns (research recommendations): Infants with
a designation of CRMS/CFSPID (by definition) do not have
clinical features consistent with a diagnosis of CF and further
research is needed to determine the prognosis and best prac-
tices for frequency and duration of follow-up. There is in-
adequate evidence to recommend a standard period and
frequency for follow-up of these individuals. Further re-
search on this will require common definitions, and the
merging of CRMS and CFSPID designations is, there-
fore, especially timely.
General Note for the Nonscreened Individual
(25) For individuals presenting with CF symptoms, the same di-
agnostic criteria recommended for the screened popula-
tion for sweat chloride testing, CFTR genetic analysis, and
CFTR functional testing should be used to confirm a CF
diagnosis.AlthoughNBS encompasses themajority of new
diagnoses, diagnosis of CF in the nonscreened popula-
tion, particularly those born before the initiation of NBS
at all accredited CF centers, still occurs. (There will also
be individuals that present with symptoms following a
false negative CF NBS result28,50 who should then be con-
sidered as in the nonscreened population.) In these in-
dividuals, the diagnostic algorithm (Figure) remains
applicable. However, the assignment of a diagnosis of
CF will be weighed against alternative diagnostic expla-
nations of the presenting symptom or feature. There-
fore, the pretest probability of CF will influence the
interpretation of sweat chloride testing, CFTR genetic
analysis, or CFTR physiologic testing. Definitive diag-
nostic criteria for nonscreened populations include the
presence of CF symptoms or a family history and sweat
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chloride ≥60 mmol/L OR presence of 2 CF-causing CFTR
mutations and sweat chloride ≥30 mmol/L or physi-
ologic testing demonstrating CFTR dysfunction.
The diagnosis of CF also can be appropriate if the above
testing is not definitive, but CFTR dysfunction is the best
explanation of the patient’s symptoms. In keeping with
the reasons for recommending genetic analysis of new-
borns diagnosed with CF (statement 7) or CRMS/
CFSPID (statement 23), we suggest that all nonscreened
individuals diagnosed with CF or a CFTR-related dis-
order also undergo genetic analysis, and they or their
families be provided with genetic counseling to clarify
the risk of disease in future pregnancies. Of course, as
with all other diseases, it should be said that phenotype
can vary in individuals with the same genotype.
For the Nonscreened Individual with an
Inconclusive Diagnosis
There are scenarios in which a given patient may not meet the
above diagnostic criteria to be diagnosed with CF but also
cannot be “ruled-out” as not having CF. Although this situa-
tion is similar to infants with CRMS/CFSPID, those classifi-
cations are not appropriate for the nonscreened populations.
(26) The diagnosis of CFTR-related disorder has been defined
as a monosymptomatic clinical entity (congenital bilat-
eral absence of the vas deferens/pancreatitis/bronchiectasis)
associated with CFTR dysfunction that does not fulfill the
diagnostic criteria for CF. Individuals with a CFTR-
related disorder27 (generally mono-organ) should be as-
sessed and followed by a CF physician to ensure that if
any additional symptoms develop that are typical of CF,
they are detected.9
(27) Clinicians should avoid the use of terms such as classic/
nonclassic CF, typical/atypical CF, and delayed CF, because
these terms have no harmonized definition and could be
confusing for families or caregivers. In these and other situ-
ations, education on clinical entities and organ patholo-
gies associated with CF and their relationship with CFTR-
related disorder should be provided to patients, families,
and primary care providers to aid in the early recogni-
tion of symptoms of CF. The CF Foundation reaffirms
the view that it is essential to avoid confusion of parents
and patients, and also caregivers, with imprecise terms
like atypical or nonclassic because early diagnosis and
more effective treatments can lead to relatively mild
disease for many years even in c.1521_1523delCTT
(legacy: F508del) homozygotes. However, it is under-
stood that some European countries will continue to
use such terminology as they pursue research on mild
cases.
ICD-10 Codes for Individuals with CFTR
Dysfunction
The ICD81 system is a medical classification list created
collaboratively by the World Health Organization to be “the
international standard for defining and reporting diseases and
health conditions. It allows the world to compare and share
health information using a common language.”82 It is an al-
phanumeric system containing codes for diseases, signs and
symptoms, abnormal findings, complaints, social circum-
stances, and external causes of injury or diseases. The ICD
system is valuable, indeed essential, for many purposes in-
cluding: (1) entry and continuation into the healthcare deliv-
ery mechanisms of some countries such as the US where the
ICD codes are an integral and required component of billing;
(2) coding death certificates internationally, thus, allowing as-
sessment of mortality data; (3) epidemiologic research; and (4)
medical economics research.
Table II. ICD-10 codes for use in individuals with CF and other CFTR dysfunctional diseases or disorders
Diseases/disorders Primary ICD-10 code Secondary ICD-10 code
CF, unspecified E84.9
CF, with meconium ileus E84.11
CF, with other intestinal manifestations (eg, DIOS) E84.19
CF, with pulmonary manifestations E84.0 Use secondary code for details such
as infectious organisms present
(eg, B96.5 for Pseudomonas aeruginosa)
CF, with acute pneumothorax E84.09 J93.83
CF, with pneumothorax not otherwise specified E84.09 J93.9
CF, with hemoptysis E84.09 R04.2
CRMS, metabolic disorder unspecified E88.89
CFSPID P09 (abnormal findings on neonatal screening)*
Or:
E88.89 (if CRMS/CFSPID is adopted
as the preferred terminology)
CFTR-related disorder
(Code the signs/symptoms as described but do not use E84.9)
Pancreatitis, recurrent
CBAVD
Bronchiectasis, chronic acquired
K85.9
Q55.4†
J47.9
Z14.1
(CF carrier status)
DIOS, distal intestinal obstruction syndrome.
*Describes positive newborn screen result with an inclusive diagnosis but only applies to the newborn period and thus cannot be used in follow-up care.
†Preferred over N46.025 (azoospermia because of a systemic disease).
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The most recent revision of the system, ICD-10, imple-
mented in October 2015, provides more than 14 400 differ-
ent codes and can be expanded to over 16 000 codes by using
optional subclassifications. It is not possible to convert ICD
Ninth Revision datasets to ICD-10. In the ICD-10 coding system,
characters 1-3 indicate the category of disease; 4-6 indicate eti-
ology, anatomic site, severity or other clinical detail of disease;
and character 7 is a placeholder for extending the code to in-
crease specificity. The designation “E” indicates endocrine, nu-
tritional, and metabolic diseases, and “J” applies to diseases of
the respiratory system.
Some CF specialists were engaged in the ICD-10 develop-
ment process, but the degree of influence was limited, and
coding for diseases or disorders caused by CFTR dysfunction
is not ideal, including the absence of a code for CFTR-
related disorder. The current ICD-10 code is undergoing re-
vision to ICD 11th Revision which is due to be completed in
2018. Participation is invited (http://www.who.int/classifications/
icd/revision/en/), and we encourage involvement by CF
caregivers.
A list of ICD-10 codes that should be used in the delivery
of care for those disorders associated with CFTR mutations
(that is, CF, CRMS/CFSPID, and CFTR-related disorder) is
shown in Table II.
Summary of Revisions to the 2008 CF
Foundation Guidelines
The basic strategy necessary for diagnosis of CF in the large
majority of individuals remains unchanged from the process
recommended in 2008.24 However, some of the diagnostic
tools presented in this document and the recommended
application of those tools in more complex clinical scenarios
do represent significant changes. A summary of the main
changes to the 2008 diagnostic algorithm is presented in
Table III.
Discussion
Although NBS is now widely implemented, the diagnosis of
CF is not always clear. A sweat test is required for confirma-
tion of CF; a sweat chloride level ≥60 mmol/L indicates a di-
agnosis of CF and a sweat chloride level <30 mmol/L indicates
Table III. Summary of revisions to the 2008 CF Foundation guidelines for diagnosis of CF
Revisions to guidelines for screened populations
2015 Consensus 200824 Comparison
• Sweat testing: same recommendation in 2008, but is not being followed and
is, therefore, re-emphasized here
• Sweat testing: should be done in everyone
• Sweat Cl−: < 30 mmol/L is normal threshold for all ages (exceptions occur) • Sweat Cl−: < 40 mmol/L was normal threshold for ages ≥6 mo (exceptions
occur)
• NPD/ICM: useful; testing should be conducted in a validated lab • NPD: limited to contributory evidence; ICM: used only in research
• CFTR mutations: use CFTR2 mutation list, with guidelines given for mutations
not included in CFTR2
• CFTR mutations: Used ACMG/ACOG panel of 23 mutations51
• Presumptive diagnosis of CF: can be made (NBS+ and 2 CF mutations or signs
and symptoms of CF; or meconium ileus) and treatment started; diagnosis
must be confirmed with a sweat test
• Not discussed
• Genetic analysis: recommended in addition to that done during NBS • Genetic analysis: recommended if not part of NBS
Revisions to guidelines for CRMS/CFSPID
2015 Consensus 200824 Comparison
• CRMS = CFSPID: now a harmonized definition • (Neither term in use)
• Repeat sweat testing recommended; NPD/ICM testing may be considered • Repeat sweat testing: every 6-12 mo, but recommendation considered to
be “evolving”
• Clinical assessment: by age 2 mo; duration and frequency of follow-up
remains to be determined
• Clinical assessment: by age 2 mo; repeat every 6-12 mo
Revisions to guidelines for nonscreened population
with inconclusive sweat chloride values
2015 Consensus 200824 Comparison
• Sweat Cl−: < 30 mmol/L is normal threshold for all ages (exceptions
occur)
• Sweat Cl−: < 40 mmol/L was normal threshold for ages ≥ 6 mo
(exceptions occur)
• Ancillary testing: NPD/ICM • Ancillary testing: NPD only
Revisions to general definitions
2015 Consensus 200824 Comparison
• CFTR-related disorder: a symptomatic entity that does not meet diagnostic
criteria for CF
• CFTR-related disorder: Individuals with 0-1 CF-causing mutations and
clinical signs (possibly multiple-organ) suggestive of CF
• Avoid terms like “atypical” or “nonclassical” CF because there is no
consensus definition of these terms
• Recommendation unchanged but greater emphasis now given to the
importance of avoiding these imprecise, potentially confusing terms in
the US.
ACMG/ACOG, American College of Medical Genetics/American Congress of Obstetricians and Gynecologists.
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that CF is unlikely. In individuals who fall into the interme-
diate sweat chloride level, 30-59 mmol/L, genetic analysis is re-
quired. Further testing for CFTR function such as NPD and
ICMmay also be indicated but should be performed in a spe-
cialized center approved for such studies. Some infants with
a positive NBS and sweat chloride levels from 30 to 59 mmol/L
or even ≤29 mmol/L and inconclusive genetic testing may be
designated as CRMS/CFSPID. Further research is needed to
determine their prognosis, best practice, and frequency of
follow-up. ■
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